Ticker Details
Solid Biosciences Inc. Solid Biosciences Inc is a life science company engaged in developing therapies for Duchenne muscular dystrophy. Its product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles.
IPO Date:	January 26, 2018
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$444.87M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.32 | 3.98%
Avg Daily Range (30 D):	$0.21 | 3.51%
Avg Daily Range (90 D):	$0.19 | 3.48%

Institutional Daily Volume
Avg Daily Volume:	.46M
Avg Daily Volume (30 D):	1.1M
Avg Daily Volume (90 D):	.98M

Trade Size
Avg Trade Size (Sh.):	93
Avg Trade Size (Sh.) (30 D):	86
Avg Trade Size (Sh.) (90 D):	90

Institutional Trades
Total Institutional Trades:	422
Avg Institutional Trade:	$1.54M
Avg Institutional Trade (30 D):	$.8M
Avg Institutional Trade (90 D):	$.83M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.89M
Avg Closing Trade (30 D):	$.66M
Avg Closing Trade (90 D):	$.72M
Avg Closing Volume:	162.29K

News

Dec 16, 2025 @ 9:51 PM Solid Biosciences Announces Duchenne Muscular Dyst... Source: Solid Biosciences Inc.

Dec 1, 2025 @ 1:00 PM Solid Biosciences Receives FDA Rare Pediatric Dise... Source: Solid Biosciences Inc.

Nov 17, 2025 @ 1:00 PM Solid Biosciences Announces Licensing Agreement wi... Source: Solid Biosciences Inc.

Nov 11, 2025 @ 1:00 PM Solid Biosciences to Participate at Upcoming Inves... Source: Nicole Anderson

Aug 1, 2025 @ 12:00 PM Solid Biosciences Reports Inducement Grants Under ... Source: Nicole Anderson

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-2.51	$-.48	$-.42
Diluted EPS	$-2.34	$-.48	$-.42
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-167.14M	$-45.78M	$-39.48M
Operating Income / Loss	$-169.7M	$-48.06M	$-41.69M
Cost of Revenue
Net Cash Flow	$-3.04M	$-77.57M	$-71.75M
PE Ratio

Splits
Oct 28, 2022	1:15